Elicera Therapeutics has signed an agreement with Baylor College of Medicine (BCM), Center for Cell & Gene Therapy regulating contract manufacturing of ELC-201, the company’s oncolytic virus armed with Elicera’s fully developed iTANK-platform for a multi-targeted attack on cancer.
This is the second collaboration between Elicera and Baylor College of Medicine (BCM), Center for Cell & Gene Therapy, a private health sciences center in Houston, Texas, for production of oncolytic viruses. BCM’s production of ELC-201 will be performed according to Good Manufacturing Practice (GMP) and is planned to be completed by mid 2023, states the company.
Upcoming phase I/II study
The viral vectors will be used in Elicera’s upcoming clinical phase I/II-study with ELC-201.
“BCM has solid experience of viral vector production and have already supplied us with oncolytic viruses for our ongoing clinical phase I/II-study with ELC-100 in neuroendocrine tumors. Thus, they are well suited to also supply us with GMP material for our upcoming clinical phase I/II-study with ELC-201,” says Jamal El-Mosleh, CEO of Elicera.
Read more: Interview: A new Swedish cell and gene therapy company has been launched
ELC-201
ELC-201 is a next generation oncolytic virus that causes direct cancer lysis and is armed with Elicera’s fully developed iTANK-platform to elicit a parallel and complementary immune response based on activation of the patients’ own killer T-cells against cancer. The T-cell response is further enhanced and sustained by incorporating an additional immune stimulating factor in ELC-201.
Photo of Jamal El-Mosleh: Elicera
